Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

nilotinib can overcome imatinib resistance because of greater potency to bind to BCR-ABL. Recent results indicate that, in patients with previously untreated chronic phase CML, nilotinib results in a faster

sti571
tyrosine
chronic phase chronic myeloid leukemia
philadelphia chromosome positive chronic myelogenous leukemia
imatinib
  • 10 views
  • 24 Mar, 2022
  • 1 location
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib (DANTE)

This is a prospective, single arm, phase II study to assess the effect of nilotinib reduced to half the standard dose for 12 months on treatment-free remission in patients with Chronic Myeloid

chronic phase chronic myeloid leukemia
remission
lipase
nilotinib
leukemia
  • 3 views
  • 27 Apr, 2022
  • 5 locations
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Parkinson's disease (PD) and Alzheimer's disease (AD). Nilotinib (Tasigna®, AMN107, Novartis, Switzerland) is approved by the FDA and is well tolerated for CML treatment at oral doses of 600-800mg daily. The

tremor
hallucinations
amn107
datscan
parkinson's disease
  • 4 views
  • 11 May, 2022
  • 1 location
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal

imatinib
monoclonal protein
platelet count
influenza vaccines
PCR test
  • 92 views
  • 22 Mar, 2022
  • 163 locations
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells

  • 0 views
  • 21 Mar, 2022
  • 1 location
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

. Objective To learn if nilotinib and paclitaxel will benefit people with rare cancers. Eligibility People age 18 and older

lymphoma
adenocarcinoma
solid neoplasm
neutrophil count
dental caries
  • 0 views
  • 19 Jun, 2022
  • 1 location
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality

approval of imatinib, additional tyrosine kinase inhibitors (TKIs) have been approved by the European Medicine Agency, including the second-generation TKIs nilotinib, dasatinib, and bosutinib and the third

tyrosine
ponatinib
imatinib
bosutinib
dasatinib
  • 1 views
  • 13 Feb, 2021
  • 1 location
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

% three months later, which was far lower than 31% of the second generation TKI and 52% of the third generation TKI. Second generation TKI dasatinib and nilotinib can overcome most imatinib

tyrosine
benzene ring
philadelphia chromosome
imatinib
prednisone
  • 0 views
  • 08 Apr, 2022
  • 1 location
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

ponatinib
dasatinib
lymphoid leukemia
myeloid leukemia
chronic myeloid leukemia
  • 0 views
  • 24 Jan, 2021
  • 11 locations
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment successfully. This strategy that includes treatment change to a more powerful treatment before treatment discontinuation has not been evaluated in any of the previous clinical trials, …

tyrosine
ponatinib
potassium
kinase inhibitor
imatinib
  • 2 views
  • 14 Feb, 2022
  • 6 locations